AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound having Formula 1:



(Formula 1)

and the pharmaceutically-acceptable salts ~~and prodrugs~~ thereof, wherein:

R_1 is pyridyl or pyrimidinyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, C_1-C_6alkylthio, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13} where R_{13} is C_1-C_3haloalkyl, phenyl, heterocycloalkyl, or heteroaryl;

W is phenyl or a 5- or 6-membered heteroaryl containing from 1 to 4 heteroatoms independently chosen from nitrogen, oxygen, and sulfur; wherein W is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

X is N or CH;

R_2 is C_1-C_7alkyl, C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, or (C_1-C_6alkoxy)C_1-C_6alkoxy; or

R_2 is phenyl(C_0-C_2alkyl) or heteroaryl(C_0-C_2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from

(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy,and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, heterocycloalkyl(C_0-C_2alkyl), and $-C(O)R_{13}$; each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino;

Z_2 is



wherein

R_8 and R_9 are independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, or halogen; and n is 0, 1, or 2;

R_{10} and R_{11} are independently

(iii) hydrogen or C_1-C_6alkyl; or

(iv) phenyl or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and $-C(O)R_{13}$;

R_3 is hydrogen or C_1-C_6alkyl, or

R_3 is C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), phenyl, or heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6 alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13}; or

R_3 is phenoxy phenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and –C(O)R_{13}.

2. (Original) A compound or salt according to Claim 1, wherein

R_1 is 3- or 4-pyridyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

W is phenyl or a 5- or 6-membered heteroaryl ring; substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

X is N or CH;

R_2 is C_1-C_7alkyl, C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, or (C_1-C_6alkoxy)C_1-C_6alkoxy; or

R_2 is phenyl(C_0-C_2alkyl) or 5- or 6-membered heteroaryl(C_0-C_2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from

(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy, and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and heterocycloalkyl(C_0-C_2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino;

Z_2 is



wherein

R_8 and R_9 are independently hydrogen, C_1-C_6alkyl, C_1-C_6alkoxy, or halogen; and n is 0, 1, or 2;

R_{10} and R_{11} are independently

(iii) hydrogen or C_1-C_6alkyl; or

(iv) phenyl or a 5- or 6 membered heteroaryl ring, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl;

R_3 is hydrogen or C_1-C_6alkyl, or

R_3 is C_3-C_7cycloalkyl(C_0-C_2alkyl), heterocycloalkyl(C_0-C_2alkyl), phenyl, or a 5- or 6-membered heteroaryl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy,

C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl; (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl; or

R_3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl.

3. (Original) A compound or salt according to Claim 2 wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino.

4. (Original) A compound or salt according to Claim 3 wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy.

5. (Previously presented) A compound or salt according to Claim 4 wherein

W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, sulfonamide, -CHO, halogen, oxo, C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_6haloalkyl, C_1-C_6haloalkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), and C_2-C_6alkanoyl

6. (Original) A compound or salt according to Claim 5 wherein

W is phenyl, pyridyl, pyrimidinyl, imidazolyl, pyrrolyl, pyrazolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, oxo, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino.

7. (Original) A compound or salt according to Claim 6, wherein W is imidazolyl, pyrrolyl, or pyrazolyl, each of which is substituted with 0 to 2 substituents independently chosen from hydroxy, cyano, halogen, oxo, C_1-C_4alkyl, C_1-C_4alkoxy, trifluoromethyl, and trifluoromethoxy.

8. (Previously presented) A compound or salt according to Claim 4 of Formula 2



(Formula 2).

9. (Previously presented) A compound or salt according to Claim 4 of Formula 3



(Formula 3).

10. (Previously presented)A compound or salt according to Claim 4 of Formula 4



(Formula 4).

11. (Previously presented)A compound or salt according to Claim 9, wherein X is N.

12. (Previously presented)A compound or salt according to Claim 9, wherein X is CH.

13. (Previously presented)A compound or salt according to Claim 7 wherein Z_2 is



wherein

R_8 and R_9 are independently hydrogen or C_1-C_6alkyl; and n is 0, 1, or 2; and

R_{10} and R_{11} are independently hydrogen, C_1-C_6alkyl, or phenyl.

14. (Original) A compound or salt according to Claim 13, wherein Z_2 is



wherein, R_{10} and R_{11} are independently hydrogen, methyl or ethyl.

15. (Original) A compound or salt according to Claim 14 wherein R_{10} and R_{11} are both hydrogen.

16. (Previously presented)A compound or salt according to Claim 15 of Formula 5



(Formula 5).

17. (Previously presented)A compound or salt according to Claim 15 of Formula 6



(Formula 6).

18. (Previously presented)A compound or salt according to Claim 15 wherein R_2 is phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which may be either directly attached or bound via a C_1-C_2alkyl linker, and each of which is substituted with 0 to 3 substituents independently chosen from:

(i) hydroxy, halogen, nitro, cyano, amino, sulfonamide, -CHO, C_1-C_6haloalkyl, and C_1-C_6haloalkoxy, and

(ii) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, (C_1-C_6alkoxy)C_1-C_6alkoxy, C_1-C_6alkylthio, mono- and di-(C_1-C_6alkyl)amino, amino(C_1-C_6alkyl), mono- and di-(C_1-C_6alkyl)amino(C_1-C_6alkyl), C_2-C_6alkanoyl, and heterocycloalkyl(C_0-C_2alkyl); each of which (ii) is substituted

with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino.

19. (Original) A compound or salt according to Claim 18, wherein

R_2 is phenyl(C_0-C_2alkyl), pyridyl(C_0-C_2alkyl), or pyrimidinyl(C_0-C_2alkyl), each of which is substituted with 0 to 3 substituents independently chosen from:

(i) hydroxy, halogen, nitro, cyano, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and

(ii) C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, (C_1-C_6alkoxy)C_1-C_6alkyl, C_1-C_4alkylthio, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), and heterocycloalkyl(C_0-C_2alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, nitro, cyano, C_1-C_4alkoxy, C_3-C_7cycloalkyl, and mono- and di-(C_1-C_4alkyl)amino.

20. (Original) A compound or salt according to Claim 19, wherein

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_4alkyl, C_1-C_4alkoxy, C_1-C_4alkylthio, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.

21. (Previously presented)A compound or salt according to Claim 20, wherein

R_3 is hydrogen or C_1-C_6alkyl, or

R_3 is C_3-C_7cycloalkyl, (C_3-C_7cycloalkyl)methyl, heterocycloalkyl, (heterocycloalkyl)C_1-C_2alkyl, phenyl, phenyl, pyridyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, or isoxazolyl, each of which is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino; or

R_3 is phenoxyphenyl, each of which phenyl rings is substituted with 0 to 3 substituents independently chosen from hydroxy, nitro, cyano, amino, halogen, C_1-C_6alkyl, C_3-C_7cycloalkyl, C_1-C_6alkoxy, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and mono- and di-(C_1-C_4alkyl)amino.

22. (Original) A compound or salt according to Claim 21, wherein R_3 is hydrogen, C_1-C_6alkyl, C_3-C_7cycloalkyl(C_0-C_1alkyl), phenyl, or phenoxyphenyl.

23. (Original) A compound or salt according to Claim 22, wherein R_3 is hydrogen or C_1-C_4alkyl.

24. (Original) A compound or salt according to Claim 1 of Formula 7



(Formula 7).

25. (Original) A compound or salt according to Claim 1 of Formula 8



(Formula 8).

26. (Original) A compound or salt according to Claim 1 of Formula 9



(Formula 9).

27. (Previously presented)A compound or salt according to Claim 24, wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy;

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and

(ii) C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), piperazinyl(C_0-C_1alkyl), piperidinyl(C_0-C_1alkyl) and morpholinyl(C_0-C_1alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_2alkoxy, and mono- and di-(C_1-C_4alkyl)amino; and

R_3 is hydrogen or C_1-C_4alkyl.

28. (Currently amended) A compound or salt ~~or form thereof~~ according to Claim 1, wherein the compound is:

1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(4-Methoxy-3-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-3-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Chloro-2-methoxy-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Fluoro-2-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Chloro-2-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(5-Chloro-2,4-dimethoxy-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(4-Methyl-3-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea;

1-(4-Chloro-3-trifluoromethyl-phenyl)-3-{3-[8-(2-pyridin-4-yl-imidazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea; or

1-(2-Methoxy-5-trifluoromethyl-phenyl)-3-{3-[8-(3-pyridin-4-yl-pyrazol-1-yl)-imidazo[1,2-a]pyrazin-6-yl]-phenyl}-urea.

29. (Currently amended) A compound or salt ~~form thereof~~ according to Claim 1, wherein the compound exhibits a IC_{50} of 1 micromolar or less in a standard in *vitro* assay of $EphB_4$ kinase activity.

30. (Currently amended) A compound or salt ~~form thereof~~ according to Claim 1, wherein the compound exhibits a IC_{50} of 500 nanomolar or less in a standard in *vitro* assay of $EphB_4$ kinase activity.

31. (Currently amended) A compound or salt ~~form thereof~~ according to Claim 1, wherein the compound exhibits a IC_{50} of 100 nanomolar or less in a standard in *vitro* assay of $EphB_4$ kinase activity.

32. (Withdrawn - Currently amended) A pharmaceutical composition, comprising a compound or salt ~~form thereof~~ according to Claim 1, together with at least one pharmaceutically acceptable carrier or excipient.

33. (Withdrawn - Currently amended) A pharmaceutical composition according to Claim 32, wherein the composition is formulated as an injectable fluid, an aerosol, a

cream, a gel, a tablet, a pill, a capsule, a syrup, ophthalmic solution, or a transdermal patch.

34. (Withdrawn) A packaged pharmaceutical composition, comprising

(a) a pharmaceutical composition according to Claim 32 in a container; and

(b) instructions for using the composition to treat a patient suffering from an disease or disorder responsive to kinase activity modulation of one or more tyrosine kinase.

35. (Withdrawn) The packaged pharmaceutical composition of Claim 34 wherein the disease or disorder responsive to kinase activity modulation is cancer or a disease characterized by pathological angiogenesis.

36. (Withdrawn) The package pharmaceutical composition of Claim 34 wherein the disease characterized by pathological angiogenesis is a cancerous tumor, macular degeneration, or diabetic retinopathy.

37-56. (Cancelled)

57. (Previously presented)A compound or salt according to Claim 25, wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy;

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and (ii) C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), piperazinyl(C_0-C_1alkyl), piperidinyl(C_0-C_1alkyl) and morpholinyl(C_0-C_1alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_2alkoxy, and mono- and di-(C_1-C_4alkyl)amino; and

R_3 is hydrogen or C_1-C_4alkyl.

58. (Previously presented)A compound or salt according to Claim 26, wherein

R_1 is 3-pyridyl or 4-pyridyl, each of which is substituted with 0 to 2 substituents independently chosen from fluoro, chloro, bromo, C_1-C_2alkyl, and C_1-C_2alkoxy;

R_2 is phenyl or benzyl, each of which is substituted with 0 to 3 substituents independently chosen from: (i) hydroxy, halogen, amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and (ii) C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_4alkyl)amino, mono- and di-(C_1-C_4alkyl)amino(C_1-C_4alkyl), piperazinyl(C_0-C_1alkyl), piperidinyl(C_0-C_1alkyl) and morpholinyl(C_0-C_1alkyl); each of which (ii) is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_2alkoxy, and mono- and di-(C_1-C_4alkyl)amino; and

R_3 is hydrogen or C_1-C_4alkyl.